Frailty and Cognitive Function Assessment of TAVI Patients
NCT ID: NCT02650388
Last Updated: 2016-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2015-11-30
2018-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurocognitive Assessment in TAVI
NCT06120946
Geriatric Assessment and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement
NCT03173079
Cognitive Outcome After Surgical and Transcatheter Aortic Valve Replacement
NCT04535076
Future Optimal Research and Care Evaluation - Aortic Stenosis
NCT06168123
Pilot Study of Cognitive and Functional Outcomes Following TAVI
NCT02089945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On the other hand, beside frailty status the main barrier to TAVI is the risk of neurological impairment. The TAVI candidate patients have specific central nervous system (CNS) issues because of neurobiological changes of aging, e.g. decreased brain weight and volume, decreased neurotransmitter system function, decreased neuronal gene expression and Alzheimer type changes (8). Neurological injury and impairment in TAVI can occur as cerebrovascular event (CVE) and/or neurocognitive dysfunction. Both forms might be clinically apparent and detected, clinically apparent but undetected and clinically silent and undetected. The two neurocognitive dysfunctions - post-operative delirium (POD) and post-operative cognitive dysfunction (POCD) - most cases remain undetected although clinically could be apparent or silent (9). POD is defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). POCD is defined by Kappetein et al., as "deterioration of intellectual function presenting as impaired memory or concentration presenting with temporal association to surgery" (9, 10). The neurological injury can be observed and/or detected by neuroimaging techniques and cognitive trajectories. Some insult caused by TAVI might remain in the clinically silent area and might be observed only as slight neurocognitive dysfunction. Analization of the incidence and underlying etiology of the neurological events may lead to identification of recently non-recognized techniques or neuroprotective strategies, devices. The most elevated incidence of CVEs is within 24 hours of TAVI. This risk of further events might be high for up to two months (11). One fifth of health-related quality of life (HRQOL) is characterized by cognitive functions. Studies and reports on cognitive, psychiatric, and/or neurological events following TAVI have focused on major and well-marked complications, e.g., stroke, TIA, and post-operative delirium (12). Meantime TAVI is associated with a high incidence (73%-84%) of silent cerebral embolism as detected by diffusion-weighted MRI (13).
Chronological age does not always reflect biological age and there is a wide range between fit to frail (14). A well established and validated frailty score based on relatively simple and feasible tests could help in our everyday practice to evaluate the prognosis of elderly people undergoing TAVI and to determine those patients who really benefit from the procedure. Post-Operative Cognitive Dysfunction (POCD) in patients undergoing TAVI (and/or SAVR) was examined in only a few studies published during the last 10 years. Examinations and investigation of finer, long-term and possibly positive post-operative cognitive outcomes following TAVI (and SAVR) are significantly under-represented in the current medical literature (15).
Hypothesis:
There is a significant correlation between the Hungarian Frailty Score (HFS) and post procedure outcomes and quality of life preservation. HFS score would be a useful tool to estimate those who will benefit from TAVI. We also hypothesize that cognitive performance will be preserved, and will improve at the end of 12th month after TAVI due to better cerebral circulation.
Objectives and aims
1. Generate and validate a new risk score system called the Hungarian Frailty Score (HFS), which represents an objective tool for evaluation of the frailty syndrome in patients undergoing TAVI procedure.
2. To determine the changes and to prove that there is no cognitive decline in patients undergoing TAVI if so any (pre and post TAVI cognitive function will be assessed).
Primary aims:
To estimate the correlation between the HFS, and the in-hospital stay, 30 day and 1-year outcomes evaluated according to the VARC 2 Criteria. The benefit of this study is to conclude exact data about quality of life and provide a comprehensive investigation of pre- and post-TAVI cognitive outcomes. We plan to define that apart from the incidence of possible neurological signs and the radiological evidences of neurogical injury and POCD, there is no decline in long term cognitive functions and there is improvement in the long term quality of life (QoL).
Secondary aims:
Find correlation and differences between HFS, QoL, eyeball test, and cognitive outcomes. Additional impact is to assess whether POD and POCD are a part of same condition, spectrum, and what can we do to prevent them.
Expected results:
To generate a simple and useable risk score system adopted to the Hungarian population for evaluating patients who undergo TAVI and collect data about post TAVI QoL and cognitive functions, and to register changes in the pre and post procedure frailty score. Non-diagnosed preoperative cognitive impairments and CVEs of the patient will be detected at baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Post TAVI neurocognitive outcome
TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective "Eyeball test", Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced.
Cognitive fuction, quality of life
To test the above score in patients undergoing TAVI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive fuction, quality of life
To test the above score in patients undergoing TAVI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Severe, symptomatic aortic stenosis,
* High risk for cardiac surgery (STS and logistic Euroscore ),
* According multidisciplinary (heart) team decision TAVI is preferable,
* Willing to participate
Exclusion Criteria
* Not willing to participate
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Semmelweis University
OTHER
Hungarian Institute of Cardiology
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ANDREKA PETER
Professor and Head of the department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Andreka, MD, PhD.
Role: PRINCIPAL_INVESTIGATOR
Hungarían Institute of Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hungarian Institute of Cardiology
Budapest, Budapest, Hungary
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
56174-1/2015/EKU(0470/15)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.